Medchemexpress LLC 1,4-Oxazepin-5(2H)-one, 4-[3-[[2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl)amino]-5-(trifluoro methyl)-4-pyrimidinyl]amino]propyl]tetrahydro- | 2543673-19-2 | 99.7% | 535.60 | 25 MG

Supplier:  Medchemexpress LLC 25MGHY160699

DCC-3116 is an orally active ULK1/2 inhibitor that functions by inhibiting KRASG12C signaling in lung cancer cells, thereby suppressing their proliferation and exhibiting anti-cancer effects. It is intended for research use only and not for patient use.

• ULK1/2 inhibitor: targets ULK1/2, playing a role in autophagy inhibition.
• Oral activity: the compound is orally active.
• Anti-cancer effects: inhibits the proliferation of lung cancer cells by inhibiting KRASG12C signaling.
• Synergistic effect: in vitro studies show a synergistic effect when combined with Sotorasib in inhibiting the proliferation of NCI-H2122 and Calu-1 cells.
• In vivo efficacy: can inhibit tumor growth in mouse models of NSCLC lung cancer, alone or in combination with Sotorasib.

Catalog No. 50-003-94611